Viome acquired Sōlaria Biō, a clinically validated synbiotics and medical foods company, expanding its personalized health platform into condition-specific products that can be offered without requiring a Viome diagnostic test.
The acquisition adds Sōlaria’s microbial discovery platform, proprietary biobank, machine-learning capabilities, and clinically studied products to Viome’s existing microbiome and RNA-based health platform.
Sōlaria’s lead product, Bōndia, will become Viome’s first commercial-stage standalone product available without a Viome test.
Bōndia is a synbiotic medical food developed for the dietary management of bone loss and was evaluated clinically under the designation SBD111.
The product was studied in a randomized, placebo-controlled trial.
Viome said Bōndia reduced femoral bone loss by 84.5% in women with osteopenia and reduced hip bone loss by up to 73.7% in women with elevated BMI or body fat.
Research supporting Bōndia has been published in Beneficial Microbes, Osteoporosis International, and the Journal of Functional Foods.
Sōlaria also has another synbiotic candidate, SBD121, currently in development for joint health.
The acquisition builds on Viome’s previous acquisition of Circulate Health and expands the company’s strategy of combining diagnostics with clinically validated interventions.
Viome has historically used RNA sequencing and microbiome analysis to provide personalized nutrition, supplement, and health recommendations.
The company said more than one million microbiomes have been analyzed through its platform.
Viome has also generated more than 140 million personalized nutritional recommendations.
The company said 94% of users who retest have shown improvements in digestion.
Sōlaria’s discovery platform is based on microbial strains identified in fruits, vegetables, and fermented foods.
Its biobank contains more than 5,700 bacterial and fungal isolates.
Sōlaria uses machine-learning models to predict the functions of individual microbial strains and identify candidates for targeted medical foods.
The company said the platform has reduced its development timeline from approximately three years from initial idea to clinical testing to about 10 months.
Viome plans to combine Sōlaria’s plant-derived microbial dataset with its own biological and microbiome data to develop additional condition-specific products.
The combined platform is intended to identify emerging health needs and match them with more targeted nutritional interventions.
The acquisition also gives Viome a broader pathway into medical foods, synbiotics, and other clinically validated consumer health products.
Bōndia is currently available through Sōlaria and is expected to become available through Viome later this year.
KEY QUOTES:
“For a decade, Viome has been helping people learn what’s happening inside their bodies because we believe true personalization is the key to improving overall health and longevity. Now, we’re building platforms that will help us expand to offer interventions people can act on immediately for health challenges they’re already facing. Powered by our vast biological dataset and Sōlaria’s biobank and discovery platform, we plan to raise the standard of efficacy in the supplement space by creating products that meaningfully improve health based on individual needs.”
Naveen Jain, Founder and CEO of Viome
“Sōlaria’s mission has always been to address health concerns at their earliest stages, when targeted nutrition can make the greatest difference. By combining our plant-derived microbial discovery engine with Viome’s ability to decode the body’s unique biological signals, we can help people recognize emerging health needs sooner and respond with precision. Together, we can offer clinically validated solutions that support people from the first signs of change in their health.”
Eric Schott, Co-Founder and COO of Sōlaria Biō
